3.6106.02% ( +0.205 )
Closed: Oct 2, 16:00:00 (EDT)Current ValuationThe current P/E ratio is -0.33, within the reasonable range, cheaper than 58.82% of the time in the past 1 years, and the industry ranks 118/602, the industry Median -2.15.
-0.331xP/E
$3.61Stock price
$-10.89Earnings per share
-0.331xP/E
Stock price$3.61Earnings per share$-10.89
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.32x
- Typical range
- -0.33x–-0.31x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
019385776
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -55.39x | 148.77% | $179.47B |
MRNAUSModerna | -24.07x | 15.53% | $75.86B |
NTRAUSNatera | -307.52x | 6.91% | $59.15B |
CSLLYUSCSL Limited | -22.68x | -- | $58.50B |
RVMDUSRevolution Medicines | -25.05x | 63.01% | $44.29B |
ROIVUSRoivant Sciences | -96.91x | 146.49% | $25.80B |
BNTXUSBioNTech SE | -12.43x | 17.09% | $24.34B |
INSMUSInsmed | -27.72x | 74.61% | $24.27B |
SMMTUSSummit Therapeutics | -15.61x | 19.75% | $13.37B |
BBIOUSBridgebio Pharma | -19.00x | 28.48% | $13.15B |
TWSTUSTwist Bioscience | -90.85x | 20.00% | $12.42B |
MDGLUSMadrigal Pharma | -35.49x | 51.06% | $11.54B |
IBRXUSImmunityBio | -10.98x | 151.32% | $10.90B |
CYTKUSCytokinetics | -10.20x | 6.37% | $9.12B |
ARWRUSArrowHead Pharma | -28.34x | 36,308.30% | $9.07B |
KYMRUSKymera Therapeutics | -29.80x | 4.94% | $8.93B |
PCVXUSVaxcyte | -7.90x | 48.80% | $8.40B |
PRAXUSPraxis Precision Medicines | -24.33x | 3.05% | $8.25B |
SYREUSSpyre Therapeutics | -54.70x | 46.89% | $8.22B |
ABVXUSAbivax SA | -17.38x | 22.49% | $8.10B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
